NGM Bio Gives Presentation Featuring Preclinical Characterization of NGM936 at 2022 ASH Annual Meeting Portfolio News / By Karina Tin December 12, 2022 NGM Bio Gives Presentation Featuring Preclinical Characterization of NGM936 at 2022 ASH Annual Meeting Read More »
Nurix Therapeutics Presents Positive Clinical Results from its Novel BTK Degrader (NX-2127) at the 64th American Society of Hematology (ASH) Annual Meeting Portfolio News / By Karina Tin December 12, 2022 Nurix Therapeutics Presents Positive Clinical Results from its Novel BTK Degrader (NX-2127) at the 64th American Society of Hematology (ASH) Annual Meeting Read More »
RAPT Therapeutics Presents Update From Its Phase 1/2 Clinical Trial for FLX475 as Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Cancer Portfolio News / By Karina Tin December 8, 2022 RAPT Therapeutics Presents Update From Its Phase 1/2 Clinical Trial for FLX475 as Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Cancer Read More »
NGM Bio Presents Preliminary Data from Phase 1 Monotherapy Dose Escalation Trial of NGM707 in Patients with Advanced or Metastatic Solid Tumors at 2022 ESMO-IO Annual Meeting Portfolio News / By Karina Tin December 7, 2022 NGM Bio Presents Preliminary Data from Phase 1 Monotherapy Dose Escalation Trial of NGM707 in Patients with Advanced or Metastatic Solid Tumors at 2022 ESMO-IO Annual Meeting Read More »
Neurona Therapeutics Presents Clinical Data for NRTX-1001 Regenerative Cell Therapy for Drug-Resistant Focal Epilepsy at American Epilepsy Society Annual Meeting Portfolio News / By Karina Tin December 5, 2022 Neurona Therapeutics Presents Clinical Data for NRTX-1001 Regenerative Cell Therapy for Drug-Resistant Focal Epilepsy at American Epilepsy Society Annual Meeting Read More »
Ribon Therapeutics Announces Acquisition of Pre-Clinical CD38 Program by Boehringer Ingelheim Portfolio News / By Karina Tin November 29, 2022 Ribon Therapeutics Announces Acquisition of Pre-Clinical CD38 Program by Boehringer Ingelheim Read More »
Cajal Neuroscience Launches with $96 Million to Transform Target and Drug Discovery in Neurodegeneration Portfolio News / By Karina Tin November 29, 2022 Cajal Neuroscience Launches with $96 Million to Transform Target and Drug Discovery in Neurodegeneration Read More »
Tenaya Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for its Gene Therapy for Genetic Arrhythmogenic Right Ventricular Cardiomyopathy Portfolio News / By Karina Tin November 28, 2022 Tenaya Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for its Gene Therapy for Genetic Arrhythmogenic Right Ventricular Cardiomyopathy Read More »
Escient Pharmaceuticals Announces $120 Million Series C Financing Portfolio News / By Karina Tin November 28, 2022 Escient Pharmaceuticals Announces $120 Million Series C Financing Read More »
Tenaya Therapeutics Announces Closing of Public Offering Portfolio News / By Karina Tin November 21, 2022 Tenaya Therapeutics Announces Closing of Public Offering Read More »
